Company profile: Exithera Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of antithrombotic and stroke prevention drug development, offering novel, potent, selective small-molecule Factor XIa inhibitors, including frunexian to prevent thrombosis without increased bleeding risk, and EP-7041 evaluated in a Phase 2 trial to prevent thrombosis in COVID-19 ICU patients and investigated to inhibit ECMO-related thrombosis while minimizing bleeding risk.
Products and services
- Factor XIa Inhibitors Development: ExIthera develops small-molecule inhibitors targeting Factor XIa to prevent thrombosis while limiting bleeding side effects
- Frunexian: A novel, potent, selective small-molecule Factor XIa inhibitor intended to prevent thrombosis without increased bleeding risk, delivering targeted antithrombotic activity
- Phase 2 Trial for EP-7041 in COVID-19 Patients: A Phase 2 study evaluating EP-7041’s safety and efficacy to prevent thrombosis in COVID-19 ICU patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exithera Pharmaceuticals
CHF Solutions
HQ: United States
Website
- Description: Provider of innovative cardiac care medical devices, designing and manufacturing a device that removes excess fluid from patients with fluid overload, offering practical solutions to address unmet clinical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CHF Solutions company profile →
Endonovo Therapeutics
HQ: United States
Website
- Description: Provider of off-the-shelf regenerative products and non-invasive electroceutical therapies, including SofPulse, a targeted microcurrent device for reducing swelling and accelerating recovery after surgery; PEMF-based treatments for cardiovascular and CNS disorders; a clinical trial in ischemic cardiomyopathy; and TVEMF technologies to mobilize stem cells and promote regeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endonovo Therapeutics company profile →
Spacelabs Healthcare
HQ: United States
Website
- Description: Provider of medical equipment and services to hospitals, clinics, and physician offices, offering patient monitoring and connectivity solutions, diagnostic cardiology, clinical informatics for collecting, analyzing, and visualizing clinical data, supplies and accessories, and Sentinel 11, a cardiology data management system enhancing security and accessibility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spacelabs Healthcare company profile →
AdvancedCath
HQ: United States
Website
- Description: Provider of advanced catheter systems and components, offering design, development and manufacturing services. Delivers high-quality, fast-response, superior solutions and proactive service through a collaborative partnership approach, serving as a fast and flexible development partner.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdvancedCath company profile →
Silk Road Medical
HQ: United States
Website
- Description: Provider of less-invasive medical devices and solutions for treating vascular diseases, specializing in carotid artery disease through proprietary trans-carotid therapies. Offers the TransCarotid Artery Revascularization (TCAR) procedure with reverse flow neuroprotection and a system that redirects blood away from the brain to capture debris before returning it to a leg vessel.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silk Road Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exithera Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exithera Pharmaceuticals
2.2 - Growth funds investing in similar companies to Exithera Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exithera Pharmaceuticals
4.2 - Public trading comparable groups for Exithera Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →